Multimodal MRI analysis of basal forebrain structure and function across the Alzheimer's disease spectrum.
Alzheimer’s Disease
Cholinergic Basal Forebrain
Functional Connectivity
Mean Diffusivity
Resting-state fMRI
Subjective Cognitive Decline
Journal
NeuroImage. Clinical
ISSN: 2213-1582
Titre abrégé: Neuroimage Clin
Pays: Netherlands
ID NLM: 101597070
Informations de publication
Date de publication:
2020
2020
Historique:
received:
03
08
2020
revised:
19
10
2020
accepted:
02
11
2020
entrez:
5
1
2021
pubmed:
6
1
2021
medline:
29
6
2021
Statut:
ppublish
Résumé
Dysfunction of the cholinergic basal forebrain (cBF) is associated with cognitive decline in Alzheimer's disease (AD). Multimodal MRI allows for the investigation of cBF changes in-vivo. In this study we assessed alterations in cBF functional connectivity (FC), mean diffusivity (MD), and volume across the spectrum of AD. We further assessed effects of amyloid pathology on these changes. Participants included healthy controls, and subjects with subjective cognitive decline (SCD), mild cognitive impairment (MCI), or AD dementia (ADD) from the multicenter DELCODE study. Resting-state functional MRI (rs-fMRI) and structural MRI data was available for 477 subjects, and a subset of 243 subjects also had DTI data available. Differences between diagnostic groups were investigated using seed-based FC, volumetric, and MD analyses of functionally defined anterior (a-cBF) and posterior (p-cBF) subdivisions of a cytoarchitectonic cBF region-of-interest. In complementary analyses groups were stratified according to amyloid status based on CSF Aβ42/40 biomarker data, which was available in a subset of participants. a-cBF and p-cBF subdivisions showed regional FC profiles that were highly consistent with previously reported patterns, but there were only minimal differences between diagnostic groups. Compared to controls, cBF volumes and MD were significantly different in MCI and ADD but not in SCD. The Aβ42/40 stratified analyses largely matched these results. We reproduced subregion-specific FC profiles of the cBF in a clinical sample spanning the AD spectrum. At least in this multicentric cohort study, cBF-FC did not show marked changes along the AD spectrum, and multimodal MRI did not provide more sensitive measures of AD-related cBF changes compared to volumetry.
Sections du résumé
BACKGROUND
Dysfunction of the cholinergic basal forebrain (cBF) is associated with cognitive decline in Alzheimer's disease (AD). Multimodal MRI allows for the investigation of cBF changes in-vivo. In this study we assessed alterations in cBF functional connectivity (FC), mean diffusivity (MD), and volume across the spectrum of AD. We further assessed effects of amyloid pathology on these changes.
METHODS
Participants included healthy controls, and subjects with subjective cognitive decline (SCD), mild cognitive impairment (MCI), or AD dementia (ADD) from the multicenter DELCODE study. Resting-state functional MRI (rs-fMRI) and structural MRI data was available for 477 subjects, and a subset of 243 subjects also had DTI data available. Differences between diagnostic groups were investigated using seed-based FC, volumetric, and MD analyses of functionally defined anterior (a-cBF) and posterior (p-cBF) subdivisions of a cytoarchitectonic cBF region-of-interest. In complementary analyses groups were stratified according to amyloid status based on CSF Aβ42/40 biomarker data, which was available in a subset of participants.
RESULTS
a-cBF and p-cBF subdivisions showed regional FC profiles that were highly consistent with previously reported patterns, but there were only minimal differences between diagnostic groups. Compared to controls, cBF volumes and MD were significantly different in MCI and ADD but not in SCD. The Aβ42/40 stratified analyses largely matched these results.
CONCLUSIONS
We reproduced subregion-specific FC profiles of the cBF in a clinical sample spanning the AD spectrum. At least in this multicentric cohort study, cBF-FC did not show marked changes along the AD spectrum, and multimodal MRI did not provide more sensitive measures of AD-related cBF changes compared to volumetry.
Identifiants
pubmed: 33395986
pii: S2213-1582(20)30332-6
doi: 10.1016/j.nicl.2020.102495
pmc: PMC7689403
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
102495Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Références
J Neurol. 2019 Oct;266(10):2465-2474
pubmed: 31227891
Neurobiol Aging. 2014 Mar;35(3):482-91
pubmed: 24176625
Neurology. 1984 Jun;34(6):741-5
pubmed: 6539435
Neurobiol Aging. 2007 Mar;28(3):398-403
pubmed: 16529847
Neurol Sci. 2013 Jul;34(7):1215-21
pubmed: 23109096
J Alzheimers Dis. 2018;64(3):801-813
pubmed: 29914027
Alzheimers Dement. 2008 Jul;4(4):265-70
pubmed: 18631977
Neuroimage. 2007 Oct 15;38(1):95-113
pubmed: 17761438
Neurosurg Clin N Am. 2011 Apr;22(2):133-9, vii
pubmed: 21435566
Acta Neuropathol. 2015 Apr;129(4):527-40
pubmed: 25633602
J Alzheimers Dis. 2019;72(2):455-465
pubmed: 31594223
Alzheimers Dement. 2014 Nov;10(6):844-52
pubmed: 24798886
Radiology. 2019 Jan;290(1):167-176
pubmed: 30351255
Neuroimage Clin. 2017 Oct 04;17:579-586
pubmed: 29201644
J Comp Neurol. 1983 Feb 20;214(2):170-97
pubmed: 6841683
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
Biol Psychiatry. 2012 May 1;71(9):805-13
pubmed: 21816388
AJNR Am J Neuroradiol. 1999 Jun-Jul;20(6):1044-8
pubmed: 10445441
Neuroimage. 2017 Feb 15;147:669-677
pubmed: 28039094
Brain Connect. 2013;3(4):353-62
pubmed: 23627661
Curr Geriatr Rep. 2018 Mar;7(1):1-11
pubmed: 29503795
Hum Brain Mapp. 2019 Feb 15;40(3):868-878
pubmed: 30311315
Ann Clin Transl Neurol. 2016 Jan 01;3(3):154-65
pubmed: 27042676
Neurology. 2000 Aug 22;55(4):484-89
pubmed: 10953178
Behav Brain Res. 2009 Jan 30;197(1):103-8
pubmed: 18786570
Science. 1982 Mar 5;215(4537):1237-9
pubmed: 7058341
Alzheimers Dement. 2014 Oct;10(5 Suppl):S344-53
pubmed: 24418052
Neuroimage Clin. 2014 Nov 27;7:105-13
pubmed: 25610772
Ann Neurol. 2002 Feb;51(2):145-55
pubmed: 11835370
Biol Psychiatry. 2010 Mar 15;67(6):588-91
pubmed: 19375072
J Comp Neurol. 1999 Sep 6;411(4):693-704
pubmed: 10421878
Front Aging Neurosci. 2017 Apr 21;9:109
pubmed: 28484387
Eur Arch Psychiatry Clin Neurosci. 2014 Sep;264(6):467-83
pubmed: 24595744
Neurology. 2020 Sep 8;95(10):e1301-e1311
pubmed: 32631924
Psychiatry Res. 2011 Dec 30;194(3):363-371
pubmed: 22078796
Front Aging Neurosci. 2017 May 04;9:127
pubmed: 28522971
Neurobiol Aging. 2004 Mar;25(3):303-10
pubmed: 15123335
Magn Reson Med. 1995 Oct;34(4):537-41
pubmed: 8524021
J Magn Reson B. 1994 Mar;103(3):247-54
pubmed: 8019776
J Alzheimers Dis. 2015;48(1):197-204
pubmed: 26401940
Ann Neurol. 1981 Aug;10(2):122-6
pubmed: 7283399
Front Syst Neurosci. 2010 May 14;4:13
pubmed: 20577591
Magn Reson Med. 2011 Sep;66(3):644-57
pubmed: 21394769
Int Psychogeriatr. 2017 May;29(5):785-792
pubmed: 28067183
Neurology. 1999 Apr 22;52(7):1397-403
pubmed: 10227624
Brain. 2018 May 1;141(5):1501-1516
pubmed: 29701787
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
J Alzheimers Dis. 2014;40(3):687-700
pubmed: 24503619
Magn Reson Med. 1996 Mar;35(3):346-55
pubmed: 8699946
Alzheimers Res Ther. 2018 Feb 07;10(1):15
pubmed: 29415768
Neuroimage. 2006 Jun;31(2):496-504
pubmed: 16473024
Neuroimage Clin. 2019;21:101612
pubmed: 30555006